Evidence map›Paper›PMID 42602399›Full record

ArticleMaterials today. Bio2026

A multitargeting nanoparticle-based vaccine for enhanced anticancer immunotherapy in HER2-Positive breast cancer.

Sen Liu, Yiqiang Zhu, Tao Chen, Xiaoqing Liu, Jintao Lai, Meilin Hu, Yaoming Liu, Haiyue Rao, Bin Zhang, Shiqi Xiao and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sen LiuSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, China.
Yiqiang ZhuInstitute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Tao ChenInstitute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Xiaoqing LiuInstitute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Jintao LaiGuangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou, 510005, China.
Meilin HuInstitute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Yaoming LiuGuangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou, 510005, China.
Haiyue RaoGuangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou, 510005, China.
Bin ZhangGuangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou, 510005, China.
Shiqi XiaoGuangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou, 510005, China.
Haojie PengGuangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou, 510005, China.
Taizhen LiangGuangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou, 510005, China.
Lixiang XieGuangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou, 510005, China.
Guochang QiuGuangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou, 510005, China.
Shan LiSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, China.
Xiancai MaSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor vaccines represent promising strategies for cancer immunotherapy. However, their application remains restricted in HER2-positive breast cancer due to poor immunogenicity and inefficient antigen presentation. Herein, a multitargeting HER2 nanoparticle vaccine, HER2_aHPF, is developed by co-displaying the HER2 extracellular domain and AE37 T-cell epitope on a

Indexed as

Cancer immunotherapiesFerritinHER2-Positive breast cancersImmune checkpoint blockade therapiesNanoparticle vaccines

Identifiers

PMID42602399
PMCPMC13473953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.